Overview

* SeaStar Medical ( ICU ) Q3 net loss narrows to $3.5 mln from $4.5 mln year-over-year

* Company raised $12.4 mln to strengthen balance sheet and fund future operations

* SeaStar Medical ( ICU ) expands QUELIMMUNE therapy to three new top-rated children's hospitals

Outlook

* Company raised $12.4 mln to support future operations

* SeaStar Medical ( ICU ) sees strong QUELIMMUNE sales in early Q4

Result Drivers

* Research and development expenses for the three months ended September 30, 2025, and 2024, were $1.9 million and $2.3 million, respectively

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.13

Q3 Net -$3.47

Income mln

Q3 $3.75

Operatin mln

g

Expenses

Q3 -$3.58

Operatin mln

g Income

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for SeaStar Medical Holding Corp ( ICU ) is $2.00, about 75% above its November 12 closing price of $0.50

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)